Answers are grounded in this paper and cite their sources.
Although clinical guidelines endorse screening for metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced fibrosis in people with type 2 diabetes (T2D), the feasibility of and barriers and considerations relevant to implementing this approach in the community remain unclear.
No takes yet. Share an insight, caveat, or question.
Gracen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: